Analysis of CROWN data (1L lorlatinib vs crizotinib) in #ALK NSCLC by EML4-ALK fusion variant and TP53 status @JTOonline. Given the clear biologic differences between variants (v3 vs others), I think it's time to stratify by variant and tailor strategies. https://t.co/iqJzIc5KEe (@StephenVLiu)

This is lorlatinib for pediatric brain cancer (at least that is my impression) neo adjuvant. We don't know the mutational profile of the child. I doubt any country in Europe would cover it. It's not lorlatinib for nsclc with alk. (@VPrasadMDMPH)

Yes. This is not even that. This is lorlatinib for ped brain cancer prior to resection. And mutations not given. Lorlatinib has more data for nsclc w alk and brain Mets. (@VPrasadMDMPH)

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer - ⁦@JTOonline⁩ (N=46) ⬆️central obesity from 27-47% ➡️ as pts get treated for years, weight gain is a serious AE #lcsm ⁦@ALKPositiveinc⁩ ⁦ https://t.co/FJlfh8BgKv (@Latinamd)

🔥🚨@OncoAlert Just out @JTOonline by our team @MayoCancerCare: #CaseReport on a sequential #SmallCell transformation & #ALK I1171T mutation as resistance mechanisms in a pt with #ALK-EML4 #NSCLC treated with combination of #Temozolomide & #Lorlatinib 👇🏼 https://t.co/GkixRkDWr5 (@RManochakian)

“Of all 3 agents, lorlatinib demonstrated the most efficacy in the brain - w an intracranial RR of 82% in patients w measurable brain metastases vs 23% in those who rec’d crizotinib. 71% of those in the lorlatinib arm w brain mets, achieved an intracranial complete response” 👇 (@Yvonne_Diaz_)

Fantastic learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: ✅Treatments such as #entrectinib and #larotrectinib ✅ Histopathology ✅Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/KEY6lBsvUT (@PresOnc_Connect)

How to choose an ALK inhibitor in first line for #NSCLC ? Unanswered question but main data regarding efficacy and safety are summarized here by Silvia Novello @myESMO advanced course. (@JulienMazieres)

#2: ctDNA dynamics in ALK+ NSCLC with lorlatinib on ph III CROWN trial ⁦@JTOonline⁩: - Molecular response calculated from baseline, mean & change in VAF - Molec R assoc w ⬆️PFS from lorlatinib - Assocn not seen w crizotinib ⁦@OncoAlert⁩ #LCSM https://t.co/QiAzlhh8ub (@DrJNaidoo)

ctDNA dynamics from the phase III CROWN trial (1L lorlatinib vs crizotinib for #ALK NSCLC) @JTOonline. Molecular response associated with longer PFS in lorlatinib arm (HR 0.37) but not crizotinib arm HR 1.48). https://t.co/4rOXceixS9 (@StephenVLiu)

From the #ASCO23 podium, @Aiims1742 lamented on the irony of better access to 3rd gen ALK inhibitors than platinum chemo in the US. Add the GI oncology stalwart 5-fu/cape to the list. (@DrR_DUNNE)

But don't forget about men too. My wife's best friend's never smoker husband presented with persistent dry cough😒 Dx w/ 7cm RML mass with supraclav node+😭 Squamous NSCLC, chemo refractory 😬 but... then found be ALK-fusion driven😁. Now in near-CR on Alectinib. 🙏🙏🙏🥂🏆😅✌️❤️ (@PatrickCMa1)

@ASCO #ASCO23 Terrific data by @JessicaJLinMD on intracranial efficacy of repotrectinib in pts with ROS1 #NSCLC @oncoalert (@CharuAggarwalMD)

#ASCO23 | Hall D1 | Sund 4:42pm CT Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1 Fusion-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) and Central Nervous System Metastases (CNS mets) in the Phase 1/2 TRIDENT-1 @JessicaJLinMD ➡️ https://t.co/I4j2RKV3WG (@MGHCancerCenter)

Explore @MatthewGKrebs & @EnriquetaFelip's results of phase 1/2 TRIDENT-1, investigating efficacy of repotrectinib in NSCLC & central nervous system metastases at 4:30pm CDT: https://t.co/qpdHw7n86b #CRUKFunded #ASCO23 @OfficialUoM @UofGlasgow (@CRUKresearch)

#ASCO23 @ASCO Poster Discussion #NSCLC phase I/II trial of APG-2449 in #ALK Efficacy seems similar across other agents in this space. @LeXiuning @OncoAlert (@CharuAggarwalMD)

APG-2449 (ALK/ROS1 and FAK TKI) #ASCO23 #LCSM (@Tony_Calles)

Fantastic in-depth overview of ALK+ #lungcancer landscape & research. Behind all these issues are people. Agree w authors @christine_lovly & @ADesaiMD: “Strategies to overcome resistance to currently available ALK inhibitors are urgently needed.” #LCSM https://t.co/YhnYYEp1Zw (@Yvonne_Diaz_)

When #MET amplification seen with resistance to #ALK inhibitors in NSCLC, is adding a MET TKI effective? Report led by Dr. @IbiayiMD @JTOonline #JTOCRR describes responses in 5 of 12 pts. More potent MET TKIs seem preferable. Safe but need to monitor tox. https://t.co/4qUcQPgtr9 (@StephenVLiu)

#ASCO23 @ASCO Abs#9017 TRIDENT-1: Repotrectinib in ROS1+ #NSCLC @ros1cancer @JessicaJLinMD Durable clinical activity seen across lines of tx @VamsiVelcheti @alexdrilon @DMSLung @EnriquetaFelip @bensolomon1 @drcheema_cancer https://t.co/SpYlYRQTL5 @OncoAlert @HemOncToday (@CharuAggarwalMD)

.@US_FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC #lcsm #oncology https://t.co/NE06iYIAlM (@OncLive)

@shikharkumar89 after reading this article feels like every ALK +ve NSCLC needs lorlatinib as their First line drug of choice. 😂😂 (@DeepakKoppaka)

Honored to receive an @ASCO @ConquerCancerFd Young Investigator Award to investigate resistance to #ALK inhibitors and activity of ALK + VEGF inhibition in advanced lung cancer. A big thanks to @RielyMD @charlesrudin and others @MSK_DeptofMed for their support! #ASCO23 (@rohit_thum)

ALK+ NSCLC Variant matters! V3- Shorter PFS with Alectinib- I would prefer Lorlatinib Excellent review on this ⬇️ https://t.co/sv2yTGQFCz @JackWestMD @DrVijayPatil11 @myESMO @IndianYoungOnco @IJMPOofficial @OncBrothers @oncologician @TargetedOnc @OncoAlert @OncLive (@shikharkumar89)

Interesting updated 2022 CROWN trial, lorlatinib should be considered one of the preferred first-line treatment options for advanced metastatic ALK+ NSCLC. @LungSummit @Lungsolutions @CAPLungCancer https://t.co/5Awopt8oBj (@Dr_Ivanoncologo)

Critical Review in Oncology Hematology. Figures to argue for using Lorlatinib as 1L treatment of advanced ALK+NSCLC. Open access. @ALKpositiveINT @ALKPositiveinc PMID:37187318. (@oncoOuLungCA)

🔥IDEAYA announces pos. interim Phs 2 data for Darovasertib & Crizotinib in Metastatic Uveal Melanoma🔥 ✅UM is difficult to treat -> we use Chemosat for liver-limited, rarely find HLA-A2+ pts, marginal benefit with ICI... 👇Intersting data -> Phase 2/3 awaited @myESMO @OncoAlert https://t.co/3yfjGlvctt (@ArndtVogel)

The combination of darovasertib and crizotinib demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma. @MeredithMcKean @SarahCannonDocs #melsm https://t.co/5zdEumnZEI (@OncLive)

Dr. @RobertoFerrara_ at #RomeLung23 discusses #NTRK as a viable target in NSCLC with two approved drugs: larotrectinib and entrectinib. Still unraveling primary and acquired resistance but newer agents like repotrectinib showing promise. (@StephenVLiu)

Dr. @oncoOuLungCA discusses #ALK NSCLC at #RomeLung23 where we have many 1L options. Will fusion variant guide treatment? Will IC50 predict best long term outcomes? CNS efficacy critical for ALK inhibitors. (@StephenVLiu)

Paper published 🤩📄 Study Evaluation Alectinib Pharmacokinetics in Hispanic Population with Advance ALK Rearranged NSCLC. Go and CHECK IT OUT! 🧬 Read 👉🏻 https://t.co/ZjVASPYmOL Thank you 👨🏻‍⚕️👩🏻‍⚕️@ogarrieta @LuisLara_M @YanHernandezP @DHeredia_onco @RealCaesarCas (@UToracica)

#CedarsSinaiCancer at #AACR23. Dr. Inderjit Mehmi @Mi_onc & Dr. Kristopher Wentzel are co-authors on “#Crizotinib in patients with solid #tumors with MET amplification or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study” @CedarsSinaiMed (@CSCancerCenter)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib https://t.co/JfPw0sNccf (@MLPOncoData)

* tyrosine kinase inhibitors, such as crizotinib, for lymphomas that express the ALK protein. (@treda10)

#TexasLung23 @JessicaJLinMD @MassGenBrigham gives an excellent talk in understanding & overcoming resistance ALK/ROS #lungcancer -30% on target 🎯 lorlatinib resistance mutations -50% unknown resistance pathways -need repeat biopsies at progression #lcsm @TLCconference (@Latinamd)

Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma | JCO Precision Oncology https://t.co/eAxXw1WY2y (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma ⁦@ESMO_Open⁩ ⁦@myESMO⁩ https://t.co/OR0vtF8PVs (@VivekSubbiah)

Clinical and Molecular Evolution of an ALK-Driven Infant-Type Hemispheric Glioma Treated Sequentially With Second- and Third-Generation Anaplastic Lymphoma Kinase Inhibitors ⁦@JCOPO_ASCO⁩ #PrecisionMedicine https://t.co/wx0ODaAWWP (@VivekSubbiah)

#TexasLung23 @JessicaJLinMD @MassGenBrigham gives an excellent talk in understanding & overcoming resistance ALK/ROS #lungcancer -30% on target 🎯 lorlatinib resistance mutations -50% unknown ROS1 resistance pathways -need repeat biopsies at progression #lcsm @TLCconference https://t.co/gNJgJsJQg5 (@Latinamd)

Taletrictinib an impressive new player for treatment of NSCLC tumors with ROS1 fusion, longer follow is needed for this disease but clear activity after Crizotinib offers chances for sequencing TKIs therapy in this subset of lung cancer patients #ELCC23 ⁦@OncoAlert⁩ (@bmassutis)

Resistance mechanism in CLIP1-LTK fusion @JSMO_official by Dr. Shunta Mori. LTK L650F resistant mutation disturbs the binding of lorlatinib, but not giltertinib (FLT3/AXL inhibitor). P-II of lorlatinib in NSCLC with LTK fusion (3L study) by LC-SRUM. #JSMO2023 #LCSM (@HHorinouchi)

30 yo F with ALK positive NSCLC with 4 BM. Treated with Lorlatinib with excellent response since 9/2022. Oligo persistent left frontal brain met. RX with SRS now? or only if progression? @SamuelChaoMD @GauravMarwahaMD @DrRoyHerbstYale @Mat_Guc @jryckman3 @drdavidpalma (@PhilBlumenfeld)